Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil falls 1% as investors watch Middle East supply disruptions
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Stifel on Neurocrine Bio. (NBIX): 'Really Nice Ingrezza Quarter, Guidance Starting to Look Potentially Conservative'
May 4, 2022 10:25 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $136.00 price target on Neurocrine Bio. (NASDAQ: NBIX).
The analyst comments "We are reiterating our Buy rating on NBIX on a strong quarter for Ingrezza ($303MM) which beat our estimate and consensus by ~$23MM and... More
Raymond James on Neurocrine Bio. (NBIX): 'Solid Beat for Ingrezza; Well Positioned Moving Forward'
May 4, 2022 10:24 AM EDTRaymond James analyst Danielle Brill reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX).
The analyst comments "Ingrezza 1Q revenues solidly beat expectations, and FY22 guidance was rea"irmed. Lighter seasonal payer headwinds and enhanced compliance helped contribute to the strong Ingrezza revenue... More
